Healthcare & Life Sciences

Healthcare & Life Sciences

Clinical Precision. Administrative Intelligence. Governed AI.

DOT partners with healthcare providers, pharmaceutical companies, and life sciences organisations to establish the data foundations, governance frameworks, and intelligent automation required to improve clinical outcomes, accelerate research, and deploy AI in compliance with the most exacting regulatory standards in any industry.

dot.com/industries/healthcare

Primary Decision-Makers

  • Chief Information Officer
  • Chief Medical Officer
  • Head of Digital Transformation
  • Chief Data Officer
  • VP R&D (Life Sciences)

Up to 35%

Admin Automation

Clinical admin AI deployment

Unified

Data Interoperability

HL7/FHIR-compliant architecture

100%

Regulatory Compliance

HIPAA, GDPR & EU AI Act aligned

Overview

Healthcare and life sciences represent simultaneously the greatest potential application domain for AI and the most complex regulatory and ethical environment in which to deploy it. The convergence of highly sensitive personal data, life-critical decision-making obligations, an intricate interoperability landscape, and a rapidly evolving regulatory framework — spanning HIPAA, GDPR, MDR, and the EU AI Act — creates transformation challenges that demand both technical precision and deep governance capability.

DOT's Healthcare & Life Sciences practice addresses three foundational imperatives: establishing data architectures that enable clinical and research intelligence without compromising patient data sovereignty; deploying administrative AI that liberates clinical and scientific staff from process overhead; and governing AI systems in strict alignment with the applicable regulatory framework — from MHRA and FDA AI/ML guidance for medical devices, through to the EU AI Act's specific provisions for high-risk AI in healthcare settings. Every engagement is designed to enhance the capabilities of clinical and research teams, not to replace the human judgement that remains central to safe, high-quality care and rigorous scientific process.

INDUSTRY CHALLENGES

The Strategic Challenges Facing Healthcare & Life Sciences Leaders

Clinical Data Fragmentation and Interoperability Failure

Healthcare organisations operate across multiple electronic health record systems, diagnostic imaging platforms, laboratory information systems, pharmacy management systems, and third-party care provider networks — each operating to different data standards and exchange protocols. The absence of HL7 FHIR-compliant interoperability prevents AI models from accessing the complete patient data record required forclinical intelligence applications, and limits the ability of life sciences organisations to aggregate real-world evidence at the scale required for research and post-market surveillance.

AI Governance in Regulated Clinical and Research Environments

AI systems deployed in clinical decision support, patient risk stratification, diagnostic assistance, drug discovery, or clinical trial design are subject to the EU AI Act's high-risk classification — imposing binding obligations around human oversight, clinical validation, technical documentation, and post-market surveillance. Organisations deploying clinical or research AI without a formal governance programme face patient safety risk, regulatory enforcement exposure, and the potential for reputational damage that is particularly acute in healthcare and pharmaceutical contexts.

Administrative Burden and Clinical Staff Capacity Constraints

Clinical staff productivity continues to be constrained by administrative processes — clinical documentation, medical coding, appointment management, referral coordination, prior authorisation, and regulatory reporting — that consume time which would otherwise be directed at patient care or research. In life sciences, regulatory submission preparation, pharmacovigilance documentation, and clinical trial data management impose analogous administrative burdens on scientific and regulatory affairs teams.

Cybersecurity Exposure in Connected Clinical and Research Environments

Healthcare and life sciences organisations represent high-value targets for ransomware, data exfiltration, and IP theft attacks — combining sensitive patient data and proprietary research assets with operational infrastructure that cannot tolerate downtime. The proliferation of connected medical devices, remote clinical access, and third-party research collaboration platforms continuously expands the attack surface, often without commensurate investment in the security capability required to manage it.

DOT SOLUTION MAP

Mapping Healthcare & Life Sciences Challenges to Intelligence-Led Outcomes

Business Challenge
DOT Solution
Measurable Outcome
Clinical data fragmentation
Data Liquidity Audit + HL7/FHIR Architecture Design
Unified clinical data estate; interoperability across EHR, diagnostics, pharmacy; AI-ready
Clinical AI governance obligations
AI Ethics Framework + EU AI Act High-Risk AI Programme
Compliant clinical AI governance; human oversight protocols; conformity assessment documentation
Administrative burden — clinical
Clinical Documentation & Coding AI Agent
65% reduction in administrative time per clinician; automated coding and referral management
Administrative burden — life sciences
Regulatory Submissions & Pharmacovigilance AI Agent
Accelerated regulatory submission preparation; automated AE reporting; trial data management
Cybersecurity and ransomware exposure
Cognitive Security + Zero Trust + IR Retainer
Connected device security; 24/7 monitoring; sub-15-min detection; guaranteed IR response

Recommended DOT Services for This Sector

Intelligent Data Foundation

Intelligent Data Foundation

HL7/FHIR Clinical Data Architecture & Governance
Design and implement a FHIR-compliant clinical data architecture enabling seamless interoperability across EHR systems, diagnostic platforms, and care networks — without compromising patient data sovereignty or GDPR processing lawfulness.
AI Strategy & Governance

AI Strategy & Governance

Clinical AI Ethics Framework & EU AI Act Readiness
Establish a governance programme satisfying EU AI Act high-risk AI obligations for clinical decision support, diagnostic assistance, and research AI — including human oversight protocols, clinical validation evidence, and post-market surveillance frameworks aligned to MHRA and FDA AI/ML guidance.
Autonomous Operations

Autonomous Operations

Clinical Administration & Life Sciences AI Agents
Deploy AI Agents automating clinical documentation, medical coding, appointment scheduling, referral coordination, regulatory submission preparation, and pharmacovigilance case processing — materially reducing the administrative burden on clinical and scientific teams.
Assurance & Trust

Assurance & Trust

Healthcare Cognitive Security & Zero Trust
AI-powered threat detection calibrated to clinical environments, connected medical device security, and a Zero Trust architecture protecting patient data and research IP without impeding clinical workflow.

Client Perspective — Multi-Site NHS Trust

Outcomes:  

  • Data Liquidity Score: 29% → 84% at Phase 1
  • Admin time per shift: 2.8 hrs → 1.1 hrs
  • Shadow AI tools governed: 17
  • GDPR compliance status: fully documented and audit-ready

Challenge

A multi-site NHS Trust operating across six hospitals faced critical interoperability challenges between three separate EHR systems with no unified patient data visibility. Clinical staff spent an average of 2.8 hours per shift on administrative tasks. Seventeen AI tools had been adopted informally by clinical departments without governance documentation or GDPR assessment.

 

DOT Approach

DOT conducted a Data Liquidity Audit producing a score of 29%, driven by the three disconnected EHR systems. An HL7 FHIR-compliant architecture was designed and implemented over twelve weeks. A Clinical Documentation AI Agent was deployed in parallel. DOT's AI Ethics Framework governed the seventeen existing AI tools and established a formal AI approval pathway for future deployments.

Healthcare & Life Sciences — FAQ

Clinical AI systems — including decision support, risk stratification, diagnostic assistance, and triage tools — are classified as high-risk under the EU AI Act. DOT’s AI Ethics Framework for healthcare includes full conformity assessment documentation, human oversight protocol design, clinical validation evidence frameworks, and post-market surveillance procedures aligned to EUDAMED registration requirements. We work directly with clinical governance, medical devices, and regulatory affairs teams to embed AI governance within existing clinical quality management structures.

HL7 FHIR (Fast Healthcare Interoperability Resources) is the international standard for exchanging healthcare information between systems. AI models require access to complete, consistently structured clinical data to function accurately. Without FHIR-compliant interoperability, clinical data from different systems cannot be combined, and AI models trained or deployed on incomplete data produce unreliable clinical outputs with patient safety implications. DOT’s data architecture work targets FHIR compliance as the non-negotiable foundation of every healthcare AI engagement.

DOT’s Life Sciences service stream addresses the distinct operational challenges of pharmaceutical companies, CROs, biotech firms, and medical device manufacturers — including AI governance for drug discovery models, automated regulatory submission preparation (CTD/eCTD), pharmacovigilance AI Agents, clinical trial data management automation, and AI Ethics frameworks aligned to FDA AI/ML-based software as a medical device (SaMD) guidance and EMA AI reflection paper. The underlying DOT methodology is consistent, but the regulatory context, data architecture, and AI governance requirements are tailored to the life sciences operating environment.

Yes. DOT’s AI Agent architecture supports integration with all major EHR and clinical information systems — including Epic, EMIS, TPP SystmOne, Cerner (Oracle Health), and System C — through HL7 FHIR APIs, SMART on FHIR application frameworks, or direct API development where native FHIR support is absent. Integration capability assessment is conducted during the initial discovery engagement and validated against the Trust’s or system’s information governance requirements.

Informal AI adoption in clinical settings carries patient safety, GDPR, and professional liability risks that are distinct from those in commercial sectors. DOT’s recommended approach begins with a Shadow AI Detection engagement to inventory all tools in use, followed by a risk classification exercise evaluated against clinical governance standards, GDPR processing lawfulness, and EU AI Act classification criteria. Tools meeting all standards are formally approved and brought under governance oversight; those that do not are subject to a managed transition to compliant alternatives, with continuity of clinical workflow maintained throughout.

Commission Your Healthcare & Life Sciences Intelligence Assessment

Partner with DOT to establish the data foundations and AI governance framework your clinical and research programmes require.

Contact Us